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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
In this article, we address the use of evidence to inform judgements about the balance between the
pros and cons of policy and programme options. We suggest five questions that can be considered
when making these judgements. These are: 1. What are the options that are being compared? 2.
What are the most important potential outcomes of the options being compared? 3. What is the
best estimate of the impact of the options being compared for each important outcome? 4. How
confident can policymakers and others be in the estimated impacts? 5. Is a formal economic model
likely to facilitate decision making?
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these decision makers. The series is intended
to help such people ensure that their decisions are well informed
by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org.  Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
Scenario
You work in the Ministry of Health. The Minister of Health has
asked you to present a summary of the expected benefits, harms
and costs of an important change in health policy that is being
considered.
Background
In this article, we suggest five questions that policymakers
and those who support them can ask when considering
how to ensure that judgements about the pros and cons of
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health policy and programme options are well-informed
by research evidence. Such questions can be asked, for
instance, in scenarios, such as the one described above.
Research alone does not make decisions [2]. Judgements
are always required, including judgements about what
evidence to use, how to interpret that evidence, and our
confidence in the evidence. More importantly, decisions
about options require judgements about whether the
anticipated desirable consequences outweigh the undesir-
able consequences (see Figure 1) [3]. In addition to mak-
ing judgements about how big the impacts are likely to be,
decision-making processes require judgements about how
important the impacts are, the resources that are required
to implement the option [4], and the extent to which the
option is a priority relative to other ways in which those
resources might be used.
It would be simple to make a decision if an option was
expected to have large benefits with few downsides and
little cost, if we were confident about the evidence and the
importance of the benefits, and if the option was a clear
priority. Unfortunately, this is rarely the case. More often
the expected impacts and costs are uncertain, and com-
plex and difficult judgements must be made.
The questions we propose here do not reduce the need for
judgements. However, more systematic considerations
and discussions of these questions could help to ensure
that important considerations are not overlooked and
that judgements are well informed. These could also help
to resolve disagreements or at least help to provide clarifi-
cation. If these judgements are made transparently they
could help others to understand the reasoning behind
health policy decisions.
Preparing and using a balance sheet (as explained in Table
1 and addressed in the first four questions discussed
below) can facilitate well-informed decision making.
Sometimes using a formal economic model, such as a
cost-effectiveness analysis, can also be helpful. This latter
issue is addressed in the fifth question discussed in this
article. The considerations we suggest here are based on
the work of the GRADE Working Group [5]. Although the
Group's focus has been primarily on clinical practice
guidelines, their approach to decisions about clinical
interventions can also be applied to policies and pro-
grammes [6].
Questions to consider
The following five questions can be used to guide the use
of evidence to inform judgements about the pros and cons
of health policy and programme options:
1. What are the options that are being compared?
2. What are the most important potential outcomes of the
options being compared?
3. What is the best estimate of the impact of the options
being compared for each important outcome?
4. How confident can policymakers and others be in the
estimated impacts?
5. Is a formal economic model likely to facilitate decision
making?
The first four questions are intended to guide the use of
balance sheets in policy decision making. Answering the
final question can help to ensure that the scarce resources
used in full economic analyses are applied where they are
needed most.
Ideally, balance sheets (and economic models) should be
constructed by researchers or technical support staff
together with policymakers. They should also be based on
systematic reviews for the same reasons described else-
where that highlight the importance of systematic reviews
in general [7]. We will not consider the many detailed
judgements that must be made when constructing a bal-
ance sheet as these have been addressed elsewhere [8].
Policymakers are rarely, if ever, in a position where they
are required to make all such judgements themselves. Yet
even in instances where there is competent technical sup-
port to prepare a balance sheet, it is important that policy-
makers know what to look for and what questions to ask.
This ensures that balance sheets can be used judiciously to
inform the decisions for which policymakers are account-
able.
Balancing the pros and cons of health policies and pro- grammes Figure 1
Balancing the pros and cons of health policies and 
programmes. Decisions about health policy or programme 
options require judgements about whether the desirable 
consequences of an option are worth the undesirable conse-
quences
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1. What are the options that are being compared?
When using a balance sheet such as the one shown in
Table 2, the first consideration is the need to identify what
options are being compared. Often this is not as straight-
forward as it sounds (see Table 3, for example). Those pre-
paring a balance sheet must decide on both the option
being considered and the comparative option. Typically,
the comparison is the status quo. However, the status quo
is likely to vary from setting to setting. Decisions need to
be made, therefore, about which characteristics of the sta-
tus quo are:
• Crucial - such that research with a comparison without
those same characteristics would be excluded
￿ Important but not crucial - such that research with a
comparison without those same characteristics would be
included, but with less confidence that the results would
be the same in the chosen setting, and
￿ Unimportant - such that we would be confident that the
results are likely be the same in the chosen setting
These same judgements also need to be made about the
options being considered: which of their characteristics
are crucial, important or unimportant in terms of affecting
the likely impacts?
2. What are the most important potential outcomes of the 
options being compared?
Policymakers, in general, are motivated by the desire to
serve the people they represent and should be interested
primarily in the impacts of policy and programme
options on outcomes that are important to those affected
(see, for example, Table 4). These include health out-
comes, access to - or utilisation of - health services, unin-
tended effects (harms), and resource use (costs or savings)
(see Figure 1). Other often important consequences
include the distribution and equity of benefits and costs
[9], and spillover effects to other sectors. Ethical conse-
quences such as those related to a reduction in people's
autonomy, may also be important.
Being explicit about which outcomes are important can
help to ensure that the important consequences of an
option are not overlooked. It can also help to ensure that
unimportant consequences are not given undue weight.
This is particularly important for surrogate outcomes - i.e.
outcomes that are not important in and of themselves.
They are considered important because they are believed
to reflect important outcomes. For example, people do
not typically regard their blood pressure as an important
concern. What makes the issue of blood pressure impor-
tant is its association with strokes, heart attacks and death,
all of which are very much of importance to people. So
when considering options targeted at hypertension (or
other cardiovascular risk factors), decisions should be
based on the impacts of these options on important out-
comes (cardiovascular disease). Evidence of impacts on
blood pressure alone is only a form of indirect evidence of
the impacts on cardiovascular disease.
3. What is the best estimate of the impact of the options 
being compared for each important outcome?
Deciding whether the desirable impacts of an option are
worth the undesirable impacts requires an estimate of
how large these different impacts (and their economic
consequences) will be. Ideally, this should take the form
of a comparison between what could be expected for every
important outcome if an option were to be implemented,
and what could be expected if it were not - or what could
be expected if a different option were implemented
instead (see Table 5, for example). It is also useful to know
how precise each estimate is - i.e. what the 'confidence
interval' is for each estimate (this is explained further in
Table 6).
Table 1: The pros and cons of balance sheets
A balance sheet is a simple but powerful way to present the advantages and disadvantages of different options, including policy options [17][23,]. In 
this section we describe the evidence and judgements needed to prepare and use a balance sheet such as the one shown in Table 2. We also 
describe the advantages of using a balance sheet compared to the use of non-systematic and non-transparent judgements of experts.
The aim of a balance sheet is to help decision makers develop an accurate understanding of the important consequences of the options being 
compared. Balance sheets help to achieve this in a number of ways. Firstly, they condense the most important information, thus enabling efficient 
consideration. Secondly, balance sheets focus attention on the most important outcomes. This increases the likelihood that decision makers will 
gain an accurate perception of what is known about the impacts of the options being considered and the important consequences. Thirdly, the act 
of constructing a balance sheet is a helpful mechanism for organising thinking, structuring evidence analysis, and focusing debate. Fourthly, balance 
sheets can help to develop more explicit judgements about what the most important consequences of policy options are, the underlying evidence, 
and subsequent judgements about the balance between the relative advantages and disadvantages of the various options. Lastly, balance sheets can 
provide other decision makers with 'raw information', thereby helping them to apply their own judgements about the trade-offs between desirable 
and undesirable consequences.
But two important limitations also need to be considered when using balance sheets in decision making. Firstly, when there are complicated trade-
offs between multiple outcomes, judgements may require a high level of information processing by policymakers. Secondly, when weighing up 
different outcomes, the value judgements employed by policymakers could remain implicit. Formal economic modelling may help to address these 
limitations by making any underlying assumptions (including value judgements) more explicit. This enables the use of sensitivity analyses to explore 
the effects of both uncertainties and varying assumptions on the results.Health Research Policy and Systems 2009, 7(Suppl 1):S16 http://www.health-policy-systems.com/content/7/S1/S16
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Table 2: Should the licensing of tobacco retailers be conditional on not selling tobacco to minors?
Population: Minors (as defined by a legal age limit)
Setting: Europe
Interventions: Licensing of tobacco retailers + compliance checks*
Comparison: No licensing or compliance checks
Impact
Pessimistic Best guess Optimistic Number of studies Quality of the Evidence 
(GRADE)‡
Reduced number of 
smokers per year
0 ? 1,650 in the country
(population 4.5 million)
4 Very low‡
Life years saved per 
year
0 ? 9,240 in the country
(population 4.5 million)
4 Very low§
Cost per year €10,5 million
(3 controls per year)
? €7,2 million
(1 control per year + 
internal control)
0 Very low**
*The proposed licensing law in the European country in question would require retailers to have a licence to sell tobacco. The policy options that 
were considered included three compliance checks per year, and one per year together with internal control. Compliance checks (by a teenager 
attempting to purchase tobacco) are done to ensure that tobacco is not being sold to minors. The penalty for non-compliance is the loss of a retail 
licence. Internal control requires the retailers themselves to have routines for controlling the sale of tobacco to minors
†See Table 8
‡The systematic review used as a basis for this summary (which was not used in the expert report to which we refer in subsequent tables) included 
one relevant randomised trial and three controlled before-after studies with important limitations. There was a high risk of bias for the estimated 
impacts on smoking prevalence. Important inconsistencies in the results lacked a compelling explanation. The studies in the review were based in 
the United States (2), the United Kingdom (1) and Australia (1), with differences in the interventions and uncertainty about whether similar results 
would be expected in the country where this policy was being considered. Two studies found an effect in lower age groups that was not sustained 
in one study; two studies did not find a change in smoking behaviour. It is difficult to estimate, based on these studies, what the best estimate would 
be of the impact of licensing of tobacco retailers with compliance checks on reducing the number of people who smoke. A lower estimate would be 
that there would be no impact from this intervention. The upper estimate is taken from an expert report (see Tables 3 5)
§The upper estimate of life years saved, which is taken from the same expert report, has the same limitations as the estimate of the impact on 
smoking behaviour, since it is based on that estimate. In addition, it is based on assumptions about what would happen long beyond the length of the 
studies that had evaluated impacts on smoking behaviour as well, and assumptions about the impact of the changes in smoking behaviour on 
mortality
**The estimates of the cost of the policy are taken from the expert report (described in subsequent tables in this article). These are based on an 
estimate of how many retailers sold tobacco, an assumption about what it would cost to process each licence, and an assumption about the costs 
of each compliance check
Table 3: What is being compared? Case example: The licensing of tobacco retailers
The reduction of teenage smoking was a priority for a Minister of Health in a European country. A report of policy options to achieve this was 
commissioned by the government concerned and a report was prepared by leading public health experts. One of the policy options considered in 
the report was the licensing of tobacco retailers. The loss of such a license was proposed as a penalty for the illegal selling of tobacco to minors. 
This option was compared in the report to the status quo, namely the absence of licensing for tobacco retailers. The public health experts did not 
undertake or use a systematic review, nor did they specify which characteristics of the policy option (or comparator) they considered to be crucial 
or important.
A number of important issues were not considered in the report. Important differences, for example, might have existed between the status quo of 
the areas where the policymakers considered implementing the policy and those where the studies were done. Such considerations may have 
included other policies already in place to reduce the sales of tobacco to minors. It is possible that existing legislation may already have made the 
sale of tobacco to minors illegal, or contained other methods by which legislation could be enforced (e.g. through fines or other penalties for the 
illegal sale of tobacco, face-to-face education of retailers (informing them about the legal requirements), or media campaigns (to raise community 
awareness). There might also have been differences in the ease with which minors could obtain tobacco from other sources (e.g. from parents and 
friends or through theft).
The experts explicitly considered two policy options for the licensing of tobacco retailers, namely three compliance checks per year (by a teenager 
attempting to purchase tobacco) to make sure that retailers were not selling tobacco to minors, and one compliance check per year together with 
internal control (requiring retailers themselves to control that tobacco is not being sold to minors). The penalty for non-compliance in both cases 
was the loss of the relevant licence. Other ways of enforcing licensing are possible, some of which have been evaluated in other studies. The 
experts writing this report did not explicitly address whether differences in approaches to licensing enforcement were likely to result in important 
differences in the effectiveness of the policy.Health Research Policy and Systems 2009, 7(Suppl 1):S16 http://www.health-policy-systems.com/content/7/S1/S16
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It is important that decision makers recognise the differ-
ence between estimates of effect that are presented as rela-
tive effects, and those that are presented as absolute effects.
Patients, health professionals, and people making deci-
sions about health policies and programmes are more
likely to decide to use an intervention if its effects are
reported as a relative effect than if they are reported as an
absolute effect [10]. For example, a study reported that
61% of a sample of health professionals in Australia
agreed to implement a colorectal cancer screening pro-
gramme that would reduce the rate of deaths from bowel
cancer by 17% (the relative risk reduction). In compari-
son, only 24% of the health professionals agreed to imple-
ment a programme that produced an absolute reduction
in deaths from bowel cancer of 0.4% (the absolute risk
reduction) [11]. Both estimates were, in fact, from the
same programme (for an explanation of the difference
between relative and absolute effects see Table 4 in Article
10 of this series [9]).
4. How confident can policymakers and others be in the 
estimated impacts?
Six factors can lower our confidence in estimates of the
impacts of a policy or programme [12]:
￿ A weak study design
￿ Other study limitations
￿ Imprecision
￿ Inconsistent results
￿ Indirectness of the evidence
￿ Publication bias
An assessment of these factors is inevitably technical. Pol-
icymakers do not need to have a detailed understanding
of these factors or how they are assessed. But both policy-
makers and their technical support staff can still benefit
from understanding why it is important to consider these
factors.
Studies in which a programme is randomly assigned
reduce the risk of unknown or unmeasured differences
between the groups being compared. This gives greater
confidence that impacts are attributable to the pro-
gramme and not some other factor [13-15]. Study designs
that do not use random assignment can account only for
differences that are measured. For example, a study in
which communities are randomly assigned to a pro-
gramme or policy option, such as the licensing of tobacco
retailers, would provide more compelling evidence of the
impacts of an option than a study would if it compared
communities that had decided themselves whether to
implement a particular option. This is because communi-
ties that decide to implement an option are likely to differ
from those that do not in ways that could have an impact
on the outcomes of interest (in this case, smoking preva-
lence). It would therefore be impossible to know whether
the differences in outcomes were due to the policy or pro-
gramme option or due to those other differences between
the communities.
Table 5: What are the best estimates of the impacts? Case example: The licensing of tobacco retailers
The expert report on policies to reduce teenage smoking commissioned by the government concerned estimated that licensing tobacco retailers 
would result in a 10% relative reduction in the number of smokers. Using the current prevalence of smokers as a reference, the absolute effect of 
the policy was estimated to be a reduction of 1,650 smokers per year. Based on epidemiological models of the increased risk of dying due to 
smoking, the experts estimated that this policy would save 9,240 lives per year. No confidence intervals were provided, although it was noted that 
the actual effect was very uncertain and a range of estimates was used to calculate the cost-effectiveness of licensing tobacco retailers. 
Administrative costs were estimated, based on an estimate of how many retailers sold tobacco, an assumption about what it would cost to process 
each licence, and an assumption about what each inspection would cost (to check compliance with the requirement not to sell tobacco to minors).
Using these different assumptions, the total estimated cost was between n7.2 million and n10.5 million per year.
Table 4: What are the most important outcomes? Case example: The licensing of tobacco retailers
The primary outcome considered by the expert report commissioned by the government concerned was the prevalence of smoking. This was 
recognised to be a surrogate outcome for the consequences of smoking. The impact on life years saved was estimated based on the estimated 
impact on the prevalence of smoking and on epidemiological data linking smoking to mortality. Impacts on morbidity were not considered. Other 
impacts that were explicitly considered by the experts were administrative costs, political acceptability and public acceptability. There are a number 
of other outcomes that the expert report could have considered, including:
• Costs to retailers and potential harms (e.g. increased theft or cross-border shopping)
• Who would pay the administrative costs of such schemes
• The potential differences in the impacts of the policy on different populations (e.g. socio-economically disadvantaged minors or those living close 
to the country's border (who could potentially cross over into a neighbouring country to purchase tobacco)
• Ethical consequences 
(e.g. those related to the use of a minor or person pretending to be a minor for compliance checks, or the fairness of the policy in relation to the 
potentially different impacts on different groups of minors and different retailers)Health Research Policy and Systems 2009, 7(Suppl 1):S16 http://www.health-policy-systems.com/content/7/S1/S16
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Other study limitations can affect both randomised and
non-randomised impact evaluations. Incomplete data or
the unreliable measurement of outcomes, for instance,
may increase the risk of an estimate being biased, and
therefore lower confidence in the derived estimates.
Imprecision (as indicated by a wide confidence interval)
also lowers the confidence with which chance can be
ruled out as a factor shaping any observed differences in
outcomes between compared groups, and consequently
our confidence in an estimated effect. (Table 6 explains
the concept of confidence intervals in further detail)
If different studies of the same policy or programme
option have inconsistent results and there is no compel-
ling explanation for such differences, there will also be
less confidence in knowing the expected impacts arising
from implementing the option.
There are several ways in which studies might not be
directly relevant to a particular question, and therefore
result in less confidence in the results. As noted above, if
an indirectly relevant outcome (such as blood pressure) is
measured in place of an important outcome (cardiovascu-
lar disease), there will be less confidence in the impacts on
the important outcome (for which the indirect outcome is
a surrogate). If only indirect comparisons are provided,
confidence will also be lower. We would be less confident
in studies of an option that lacked head-to-head compar-
isons, for example, between the option compared to a
control (with no intervention) and studies of a different
option compared to a control. Other ways in which evi-
dence can be indirect include differences between a study
and the setting of interest in:
￿ The characteristics of the population
￿ The option being considered, or
￿ The status quo or comparison option
Studies that find statistically significant effects are often
more likely to be published than those that do not [16].
When such 'publication bias' appears likely, confidence in
estimates from published studies alone may also be low-
ered. Publication bias should be considered in instances
where there are a number of small studies, especially if
these are industry-sponsored, or if the investigators are
known to share other similar conflicts of interest.
In summary, assessments of the 'quality' or robustness of
evidence, and confidence in estimates of the likely
impacts of options, depend on a consideration of all of
the factors noted above. Although there are no fixed rules
for assessing these factors, judgements related to the qual-
ity of evidence that explicitly address each factor help to
reduce the likelihood of important factors being over-
looked. They also help to reduce the probability of biased
assessments of the evidence (see Table 7, for example).
Using a systematic and transparent approach, such as the
GRADE approach (see Table 8), makes it easier to inspect
the judgements made [5].
Table 7: How confident are we in the estimated impacts? Case example: The licensing of tobacco retailers
The expert report commissioned by the government concerned concluded that the empirical basis for the licensing of tobacco retailers was 
"robust" but the basis for this judgement was unclear. The experts did not conduct, or cite, the systematic review that is referenced in Table 3, or 
any other systematic review as the basis for their estimates, even though a systematic review was available [24]. In contrast to the experts' 
unexplained judgement, an assessment of the evidence summarised in the systematic review using the GRADE approach, suggests that the quality of 
the evidence was very low for all the important outcomes (see Table 8 for further information related to the GRADE assessment system). Table 1 
summarises the findings of the experts' report in the form of a balance sheet for this policy decision and shows an assessment of the quality of the 
evidence for the three estimates using the GRADE approach.
The authors of the systematic review (which included a broader range of interventions and study designs) concluded: "Interventions with retailers 
can lead to large decreases in the number of outlets selling tobacco to youths. However, few of the communities studied in this review achieved 
sustained levels of high compliance. This may explain why there is limited evidence for an effect of the intervention on youth perceptions about ease 
of access to tobacco, and on smoking behaviour." The 'pessimistic' estimates of the benefits in Table 1 are consistent with the findings of the 
systematic review and were not considered in the expert report.
Table 6: Confidence intervals
A confidence interval (CI) is the range around an estimate which conveys how precise the estimate is. The confidence interval is a guide that 
represents how sure it is possible to be about the quantity we are interested in (e.g. the effect of a policy option on an outcome of interest). The 
narrower the range between the upper and lower numbers of the confidence interval the more precise the estimate is and the more confident it is 
possible to be about the true value. The wider the range the less certain it is possible to be. The width or range of the confidence interval reflects 
the extent to which chance may be responsible for an observed estimate (wider intervals reflect the greater likelihood of chance being a factor). A 
95% CI means that we can be 95% confident that the true size of an effect is between the lower and upper confidence limit. Conversely there is a 
5% chance that the true effect is outside this range.Health Research Policy and Systems 2009, 7(Suppl 1):S16 http://www.health-policy-systems.com/content/7/S1/S16
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5. Is a formal economic model likely to facilitate decision 
making?
Formal economic models, such as cost-effectiveness anal-
yses and cost-utility analyses, can help to inform judge-
ments about the balance between the desirable and
undesirable consequences of an option [17]. Economic
models can be valuable for complex decision making and
for testing how sensitive a decision is to key estimates or
assumptions. A model, though, is only as good as the data
on which it is based. When estimates of benefits, harms or
resource use come from low-quality evidence, the results
will necessarily be highly speculative (an example is pro-
vided in Table 9).
A full economic model is more likely to help to inform a
decision when there is:
￿ A large difference in the resources consumed between
the compared options
￿ Large capital investments are required, such as the con-
struction of new facilities
￿ Uncertainty about whether the net benefits are worth
the incremental costs
￿ Good quality evidence regarding resource consumption
An economic model can also be used to clarify informa-
tion needs by exploring the sensitivity of an analysis to a
range of plausible estimates.
Unfortunately, published cost-effectiveness analyses, par-
ticularly those undertaken for drugs, have a high probabil-
ity of being flawed or biased. They are also specific to a
particular setting which may differ in important ways
from the setting of interest [18]. Policymakers may thus
consider developing their own formal economic models.
To do this, they must have the necessary expertise and
resources.
Conclusion
Policy decisions are informed by assessments of the bal-
ance between the pros and cons of options. As we have
recommended, these should be done systematically and
transparently. When the net benefit (i.e. the difference
between the desirable and undesirable consequences) is
large in relation to the costs, we are more confident about
a decision. When the net benefit is small in relation to the
costs, we are less confident.
Generally, the less confident we are about the likely
impacts of an option, the less confident we will be when
deciding what to do. There are exceptions to this: firstly,
we may have so little confidence about the impacts of
something that it is easy to decide not to do it.
Secondly, even if there is little confidence in the benefits
of a particular option it may be easy to decide to do some-
thing simply because there is little or no risk of harm, it
doesn't cost much, and it might do some good. Many
types of health information could be categorised as such.
Policymakers, though, should be cautious about assum-
ing that seemingly harmless polices and programmes can-
Table 9: Is a formal economic model likely to help? Case example: The licensing of tobacco retailers
The expert report commissioned by the government concerned included an economic analysis. This concluded that the cost per life year saved by 
licensing tobacco retailers and conducting compliance checks was between approximately n900 and n92 000 with a best estimate of n8 000. The 
authors noted that there was substantial uncertainty about their estimates and suggested focusing on the range of estimates rather than the best 
estimate. Nevertheless they reported exact estimates (based on the assumptions they made) and concluded that the empirical basis for 
recommending licensing tobacco retailers was robust. As a result policymakers who failed to read this report critically could conclude (wrongly in 
our opinion) that the report provided high-quality evidence that the licensing of tobacco retailers was as cost-effective as (or more cost-effective 
than) a wide range of clinical preventive services paid for by the government. A more systematic review of the underlying evidence [24] and a 
summary of the findings that included more systematic and transparent judgements of the quality of the evidence (as shown in Table 1) would have 
provided a better basis for decision making.
Table 8: The GRADE system for assessing the quality of evidence
Evaluating the quality of evidence requires judgements about the extent to which one can be confident that an estimate of effect is correct. GRADE 
provides a systematic and transparent approach to making these judgements for each outcome important to a decision [12]. The judgements are 
based on the type of study design (randomised trials versus observational studies), the risk of bias (study limitations), the consistency of the results 
across studies, and the precision of the overall estimate across studies. Based on these considerations for each outcome, the quality of the evidence 
is rated as high, moderate, low, or very low, using the following definitions:
High Confident that the true effect lies close to that of the estimate of the 
effect
Moderate The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different
Low The true effect may be substantially different from the estimate of the 
effect
Very low Very uncertain about the estimateHealth Research Policy and Systems 2009, 7(Suppl 1):S16 http://www.health-policy-systems.com/content/7/S1/S16
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not do harm [19]. Even something as simple as providing
health information can, in fact, be deadly [20]. This is
demonstrated by the advice given to mothers in many
countries for nearly 50 years, that babies should sleep on
their front. The seemingly harmless advice caused tens of
thousands of deaths from sudden infant death syndrome
[21].
Finally, despite important uncertainty about the likely
impacts of a policy or programme, it may be easy to come
to a decision that something that is promising should
only be done in the context of a well-designed evaluation
of its impacts [22].
Even when we are confident about the impacts of a policy
or programme, it may not be a priority to implement it.
The extent to which we are confident is a critical factor for
deciding on what to do and the extent to which doing
something is a priority. Other additional factors (such as
those described in Table 10) may also determine whether
policy or programme implementation is a priority or not.
Resources
Useful documents and further reading
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, Schunemann HJ, and the GRADE Work-
ing Group. GRADE: An emerging consensus on rating
quality of evidence and strength of recommendations.
BMJ 2008; 336:924-6.
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y,
Schunemann HJ, and the GRADE Working Group. What
is 'quality of evidence' and why is it important to clini-
cians? BMJ 2008; 336:995-8.
- Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M,
Vist GE, Schunemann HJ, and the GRADE Working
Group. Incorporating considerations of resource use. BMJ
2008; 336:1170-3.
Links to websites
- SUPPORT Summaries: http://www.support-collabora
tion.org/index.htm - Concise summaries of the pros and
cons of health policies and programmes for low- and mid-
dle-income countries based on systematic reviews.
- GRADE Working Group: http://www.gradeworking
group.org - The Grading of Recommendations Assess-
ment, Development and Evaluation (or GRADE) Working
Group has developed an approach to grading the quality
of evidence and the strength of healthcare recommenda-
tions.
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Table 10: Factors that can determine the importance of implementing health policies and programmes
The following factors may sometimes be considered independently (or in combination) as criteria for setting priorities for implementing health 
policies and programmes:
• How serious the problem is -- the more serious a problem is, the more likely it is that a policy or programme that addresses the problem will be 
a priority
• The number of people that are affected by the problem -- the more people who are affected, the more likely it is that a policy or programme that 
addresses the problem will be a priority
• Benefits -- the larger the benefit, the more likely it is that a policy or programme will be a priority
• Adverse effects -- the greater the risk of undesirable effects, the less likely it is that a policy or programme will be a priority
• Resource use (costs) -- the greater the cost, the less likely it is that a policy or programme will be a priority
• Cost-effectiveness -- the lower the cost per unit of benefit, the more likely it is that a policy or programme will be a priority
• Impacts on equity -- policies or programmes that reduce inequities may be more of a priority than ones that do not 
(or ones that increase inequities)
Decisions about priorities should rest on shared criteria or reasoning such as the ideas shown above. They should also be open to inspection and 
they should be possible to appeal in light of considerations that stakeholders may raise. Regulation should ensure that these three conditions are 
met [25]. When criteria such as the above are used implicitly rather than explicitly, it is difficult to judge whether the criteria or the decisions were 
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